
Keywords: Phospholipase A2; Gut microbiota; Cardiometabolic disease; Bariatric surgery; Lysophospholipid; HFHC; High fat high carbohydrate; LPC; Lysophosphatidylcholine; LPCAT3; Lysophosphatidylcholine acyltransferase-3; PLA2G1B; Group 1B phospholipase A2; TMA; Tri